Home > Gastroenterology > Neoadjuvant cemiplimab promising for resectable liver cancer

Neoadjuvant cemiplimab promising for resectable liver cancer


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
The Lancet Gastroenterology and Hepatology
Reuters Health -  27/01/2022 - Neoadjuvant cemiplimab induced pathological responses in one-third of patients with resectable hepatocellular carcinoma (HCC) in an ongoing phase II trial.  "In this trial, we are only giving roughly three weeks of therapy prior to surgery," Dr. Thomas Marron of the Icahn School of Medicine at Mount Sinai in New York City told Reuters Health by email. "The goal was not necessarily to kill the tumor we were going to remove - these patients are going to the operating room regardless - but rather to prime the immune system as to what the tumors look like, so it can recognize and eliminate any microscopic disease that remains elsewhere in the body that will eventually lead to recurrence."


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on